

# Irene Ferrer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1612532/publications.pdf>

Version: 2024-02-01

27  
papers

1,400  
citations

430442

18  
h-index

525886

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2766  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
2	RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. <i>Cancer Research</i> , 2012, 72, 2879-2888.	0.4	172
3	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. <i>Human Pathology</i> , 2013, 44, 1973-1981.	1.1	87
4	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e90524.	1.1	65
5	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	2.3	62
6	PPP1CA contributes to the senescence program induced by oncogenic Ras. <i>Carcinogenesis</i> , 2007, 29, 491-499.	1.3	61
7	Characterization of the p53 Response to Oncogene-Induced Senescence. <i>PLoS ONE</i> , 2008, 3, e3230.	1.1	41
8	Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. <i>Cell Cycle</i> , 2011, 10, 2751-2762.	1.3	40
9	Spinophilin loss contributes to tumorigenesis in vivo. <i>Cell Cycle</i> , 2011, 10, 1948-1955.	1.3	31
10	Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. <i>PLoS ONE</i> , 2010, 5, e9305.	1.1	28
11	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 130, 612-624.	3.9	27
12	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. <i>Disease Markers</i> , 2016, 2016, 1-12.	0.6	26
13	The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. <i>Scientific Reports</i> , 2018, 8, 2394.	1.6	26
14	Stromal signatures in endometrioid endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 631-639.	2.9	23
15	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). <i>Oncotarget</i> , 2016, 7, 67033-67046.	0.8	23
16	The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. <i>Human Pathology</i> , 2014, 45, 942-951.	1.1	21
17	Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. <i>Journal of Pathology</i> , 2011, 225, 73-82.	2.1	20
18	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 195.	3.5	20

#	ARTICLE	IF	CITATIONS
19	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	2.7	15
20	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Disease Markers, 2016, 2016, 1-14.	0.6	13
21	Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. Clinical Lung Cancer, 2017, 18, 667-674.e1.	1.1	13
22	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, 2019, 131, 112-121.	0.9	12
23	A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 429-438.	2.4	10
24	Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget, 2018, 9, 19945-19960.	0.8	6
25	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells, 2019, 8, 806.	1.8	3
26	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. Journal of Clinical Medicine, 2022, 11, 1500.	1.0	3
27	Osimertinib in EGFR -mutant NSCLC: how to select patients and when to treat. Lancet Oncology, The, 2016, 17, 1622-1623.	5.1	2